Latest / Public Health Review Morning Edition / 1040: Michigan’s Chief Medical Executive Discusses the Stakes of ACIP’s Vote on Hepatitis B Vaccine for Newborns
Transcript
- 0:00This is Public Health Review MORNING Edition for Wednesday,
- 0:03December 10th, 2025. I'm John Sheehan with news from
- 0:06the Association of State and Territorial Health Officials.
- 0:10Last week, the CDC's Advisory Committee on Immunization
- 0:13Practices, or ASIP, voted to narrow its guidance for
- 0:17administering the hepatitis B vaccine to newborns.
- 0:20Today, we'll discuss that guidance, what it is, and its
- 0:23ramifications with Doctor Natasha Bogdisarian, Asto's
- 0:27liaison to the advisory committee, and Michigan's Chief
- 0:30Medical Executive. Dr. Natasha Bhagdasarian,
- 0:34welcome to the show. Thanks for having me on.
- 0:36Doctor Bhagdasarian, you're Asto's liaison to the Advisory
- 0:41Committee on Immunization Practices.
- 0:43What does that mean? That means I get to attend the
- 0:46meetings. I don't get to vote, but there
- 0:49is a portion of the meeting where I can make comments on
- 0:53behalf of ASTO. And let's dig right into the
- 0:56news of the day the committee voted to narrow its guidance on
- 1:03the hepatitis B vaccine for newborns.
- 1:06Could you tell us what the committee decided, how it voted
- 1:09and kind of what it means? What I thought was really
- 1:13interesting, number one, is the type of evidence they heard
- 1:18during the meeting, essentially the people from ACIP who were
- 1:22presenting and who were really given a lot of time to speak.
- 1:26We're not physicians or people with a lot of background in
- 1:30vaccinology. We had folks who were, you know,
- 1:34environmental scientists, mathematicians who were really
- 1:37speaking about vaccines. And one of the things that I was
- 1:41really struck by in the way that ACIP went in the direction they
- 1:46voted was the language around individual decisions and shared
- 1:52clinical decision making. Meaning that they really sort of
- 1:56pull back on their broad public health guidance on the guidance
- 2:01that we all depend on and really seem to be narrowing this as an
- 2:06individual decision for babies born to hepatitis B negative
- 2:10mothers. And, and that was a little bit
- 2:12troubling to me for a number of reasons.
- 2:15Sure. Could you expand on that?
- 2:17It was, it was troubling to me because number one, we know that
- 2:20we live in a very imperfect health system.
- 2:24We live with a very imperfect health system.
- 2:27We know that there are folks who slip through the cracks.
- 2:30So there was an emphasis on how do we improve hepatitis B
- 2:34screening for pregnant women. That, of course, would be ideal,
- 2:37but we know how incredibly hard it is when we look at congenital
- 2:41syphilis and we look at how many pregnant women are missed with
- 2:44our with our syphilis screening and how many babies are
- 2:47therefore born with congenital syphilis every year.
- 2:50So we know that it's an imperfect system.
- 2:52We know that people fall through the cracks.
- 2:55We also know that hepatitis B is not only transmitted from mother
- 2:59to baby, but there can be transmission from other
- 3:02household members and that that neonatal period is a time period
- 3:07when infants are very susceptible to infection with
- 3:11hepatitis B that could become fulminant, that could become
- 3:14chronic. And so leaving this as an
- 3:18individual decision for babies born to hepatitis B mothers
- 3:22troubled me because of #1 folks who slipped through the cracks,
- 3:27folks who, number one, don't receive hepatitis B testing
- 3:30during pregnancy or those whose results are lost or misrecorded,
- 3:35which we know happens. And the second issue to me is
- 3:39this issue of other exposures, other sources of exposure to
- 3:44hepatitis B and neonates that really wasn't addressed.
- 3:47They focus solely on maternal exposure.
- 3:51So it was troubling to me that we focus so much on individual
- 3:54decision making for babies born to hepatitis B, negative mothers
- 3:58for those reasons. And also because when we start
- 4:01talking about shared clinical decision making, having this
- 4:05really be an individual decision, it really puts a lot
- 4:08of unnecessary weight and pressure on the clinicians and
- 4:14on patients. People are looking for broad
- 4:17guidance. They're looking for what does
- 4:18the CDC recommend. They were looking for a broad
- 4:22set of recommendations that can then be tailored.
- 4:24And when we don't give clinicians and patients a broad
- 4:28set of recommendations, it makes people feel that, number one,
- 4:31all of the pressures on them to make this decision and #2 it
- 4:34makes them feel that there is something really controversial
- 4:38about this particular vaccine, that there's not data or that
- 4:42there's a reason for them to be concerned.
- 4:44For clinicians, I hear often that they're concerned about
- 4:48extra documentation that they need in terms of the shared
- 4:51clinical decision making. Do they need a special form for
- 4:54this? Do they need to worry about
- 4:57extra liability when they're recommending this vaccine?
- 5:00And so those are my concerns with the direction that they
- 5:04headed and I did raise those concerns on the call.
- 5:09And the vaccine for the last 30 years has been credited with
- 5:14reducing infant rates of hepatitis B by some, some very
- 5:19large percent, 90 plus percent. So what are the what are the
- 5:26possible ramifications from sort of softening that guidance?
- 5:30You know, I think we have to think about the individual
- 5:33ramifications. I think we have to think about
- 5:35babies who could be missed, who could fall through the cracks,
- 5:38as I mentioned. And then I think we have to
- 5:39think about the broader implications.
- 5:42Will healthcare providers and the public, will they see
- 5:46hepatitis B vaccine in general as being something that's
- 5:49controversial? Will we see rates of hepatitis B
- 5:54vaccine at all ages start to decline?
- 5:58And then we also know that when we sort of raise the specter of
- 6:04scientific uncertainty, the way that was done in this meeting,
- 6:07even if it doesn't really exist, when we raise this issue and
- 6:11make it a thing, if you will, it can also impact other vaccines.
- 6:17We saw that with COVID and the COVID vaccine.
- 6:20There was a lot of controversy and a lot of political rhetoric
- 6:23around the COVID vaccine. And it's impacted our childhood
- 6:26vaccination rates. It's impacted other vaccines.
- 6:29And I wonder if what has now happened around hepatitis B
- 6:33vaccine will also impact other vaccines.
- 6:36What are some other possible consequences of of this
- 6:40decision? Well, you know, we, we have of
- 6:43course seen hepatitis B rates decline in our nation.
- 6:47Are we going to start seeing those rates coming back up?
- 6:50Are we going to start seeing more school age kids who haven't
- 6:54received not only their hepatitis B vaccine, but other
- 6:58vaccines? Here in my state of Michigan, we
- 7:00have seen a steady decline in vaccination rates for
- 7:03kindergarteners and 7th graders across the board.
- 7:07And then when we do a deeper dive and look at communities,
- 7:10there are some particular communities with very low
- 7:14vaccination rates, leaving them vulnerable for outbreaks of
- 7:16disease. Yeah, and this is something that
- 7:20would apply to all communities and States and territories
- 7:23equally, but the impacts would not be felt equally.
- 7:27I agree with you. I think that when we think about
- 7:32vaccines, we've really got to think about disparities.
- 7:35We know that there are disparities that already exist
- 7:38with vaccine uptake. There are racial disparities,
- 7:42there are socio economic disparities, geographic
- 7:44disparities. And when we think about who
- 7:48could be most impacted by a policy like this, it is
- 7:52definitely those who are more disadvantaged.
- 7:56It is socio economically disadvantaged communities,
- 7:59people who are relying on, for example, the vaccines for
- 8:01children program, people who are relying on Medicaid, I think who
- 8:05have the most to lose here. And for clarification, when
- 8:11we're speaking about what parents should do, what guidance
- 8:14they need when considering the hepatitis B vaccine, what do you
- 8:18recommend parents think about and how how should they weigh
- 8:23this decision? You know, I think that everyone
- 8:27is trying to make the best decision possible.
- 8:30One of the things that I have to remind myself is that no one is
- 8:33making vaccine decisions based on solely their political
- 8:38ideologies. People are really making
- 8:41decisions based on what they think is best for their kids.
- 8:44Everyone is sort of struggling with what is the best thing for
- 8:47me to do here? What is the best data?
- 8:49What's the best evidence? And I think it's really
- 8:52troubling right now when we have respected governmental bodies
- 8:58like ACIP who are raising controversy, perhaps even
- 9:04creating controversy around vaccines that have long been
- 9:08established. But I think that where we still
- 9:13can leverage trust, right? We we are seeing trust eroded in
- 9:17governmental agencies, in public health agencies.
- 9:19But where we can still leverage trust is in those individual
- 9:22relationships, in a relationship between a patient and their
- 9:26healthcare provider. People might not trust big
- 9:29government. They might not trust the CDC
- 9:31right now. They might not trust their state
- 9:33public health agency. But they do trust their
- 9:37pediatrician, they trust their school nurse, they trust their
- 9:41local pastor, their community leaders.
- 9:44And so I think where we can really leverage those sources of
- 9:49local trusts, those relationships are going to be
- 9:52helpful. And so a lot of what I try to do
- 9:54is talk to physicians so that physicians are quit or other
- 9:59healthcare providers are equipped to talk to their local
- 10:02community members. A lot of folks now get their
- 10:05vaccines in pharmacies. We've got to make sure that
- 10:08pharmacists have the best available data and we've got a
- 10:10leverage on the trust that still exists.
- 10:14And what is the guidance from the Michigan Department of
- 10:18Health and Human Services? Well, like many states, we have
- 10:22broken with the CDC and ACIP on this particular guidance.
- 10:28So we issued a statement several weeks ago saying that in terms
- 10:32of our childhood vaccination guidance, we were going with the
- 10:35American Academy of Pediatrics and the American Academy of
- 10:37Family Practice, which many states have done as well.
- 10:41And so for hepatitis B, we are again going with AAP, American
- 10:46Academy of Pediatrics. They continue to recommend a
- 10:48birth dose, as do we. And can you leave us with any
- 10:53sort of final thoughts on how to how to consider this situation,
- 10:57how to think about it? I think that's a really
- 11:00interesting question because we're in a position now where as
- 11:03public health leaders, we have seen our institutions be eroded.
- 11:08We've seen science, the scientific method is, is
- 11:12question not only data and recommendations, but the whole
- 11:16scientific methodology is being questioned.
- 11:18And it's it's again really difficult.
- 11:20And I think we have to think now about how do we best communicate
- 11:24with folks? How do we keep those channels of
- 11:26communication open? How do we listen and understand
- 11:29that people truly are coming to this conversation with real
- 11:32doubts rather than political ideologies?
- 11:36I think what started at the national level as political
- 11:39rhetoric has now become people's very real concerns on on how to
- 11:45proceed with vaccinating their kids.
- 11:48And again, we've got to leverage those local sources of trust,
- 11:51the people in our communities who parents know and trust.
- 11:57Well said, Doctor Natasha Bogdesarian, thanks so much.
- 12:00Thanks for having me on. Doctor Natasha Bogdesarian is
- 12:05the Michigan Department of Health and Human Services chief
- 12:07medical executive and Asto's liaison to the CDC's Advisory
- 12:11Committee on Immunization Practices.
- 12:15In the first installment of a new ASTO webinar series, state
- 12:18leaders from Iowa, Indiana, Washington, and Georgia share
- 12:21innovative tools and strategies for partnership management,
- 12:24relationship evaluation, and customer service, and public
- 12:27health. Panelists explore a range of
- 12:30approaches, from low code and no code CRM development to tailored
- 12:34feedback systems and RFP planning that support
- 12:37infrastructure improvements and more responsive engagement with
- 12:40local jurisdictions and community partners.
- 12:43Find a link to the webinar, Public Health Approaches to
- 12:45Relationship and Partnership Management, in the show notes.
- 12:50And at no point in time has the importance of public health been
- 12:53more evident. Visit publichealthcareers.org to
- 12:56explore public health resources, careers and internship
- 12:59opportunities. Connect with local, state and
- 13:01territorial health departments, and join us in our efforts to
- 13:04protect and promote the health and well-being of all Americans.
- 13:07That's public health careers.org.
- 13:10This has been Public Health Review MORNING Edition.
- 13:12I'm John Sheehan for the Association of State and
- 13:15Territorial Health Officials.